Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.

[1]  W. Rawlinson,et al.  Diversity of antiviral‐resistant human cytomegalovirus in heart and lung transplant recipients , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  E. Puchhammer-Stöckl,et al.  Deep Sequencing Reveals Highly Complex Dynamics of Human Cytomegalovirus Genotypes in Transplant Patients over Time , 2010, Journal of Virology.

[3]  I. Lautenschlager.  CMV infection, diagnosis and antiviral strategies after liver transplantation , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  W. Hall,et al.  Kinetics of host immune responses and cytomegalovirus resistance in a liver transplant patient , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  K. Olthoff,et al.  Increased incidence of cytomegalovirus infection in high‐risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  O. Manuel,et al.  Cell‐Mediated Immunity to Predict Cytomegalovirus Disease in High‐Risk Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  K. Green,et al.  Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high‐risk liver transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  H. Agut,et al.  Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. , 2009, Antiviral research.

[9]  P. Klenerman,et al.  Polyfunctional Cytomegalovirus‐Specific CD4+ and pp65 CD8+ T Cells Protect Against High‐Level Replication After Liver Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  D. Lilleri,et al.  Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. , 2008, Transplantation.

[11]  Nina Singh,et al.  Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus‐seronegative liver transplant recipients of cytomegalovirus‐seropositive donor allografts , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  R. Razonable,et al.  Emergence of drug‐resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes , 2007, Clinical transplantation.

[13]  W. Kremers,et al.  Delayed‐onset primary cytomegalovirus disease after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  J. Ziegler,et al.  Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  S. Bonon,et al.  Detection and monitoring of human herpesvirus 7 in adult liver transplant patients: impact on clinical course and association with cytomegalovirus. , 2007, Transplantation proceedings.

[16]  A. Limaye,et al.  Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. , 2007, The Journal of infectious diseases.

[17]  L. Krogerus,et al.  Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[18]  E. Puchhammer-Stöckl,et al.  Emergence of Multiple Cytomegalovirus Strains in Blood and Lung of Lung Transplant Recipients , 2006, Transplantation.

[19]  R. Fontana,et al.  Efficacy and safety of low‐dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  J. Roberts,et al.  Development of Multiplex PCRs for Detection of Common Viral Pathogens and Agents of Congenital Infections , 2005, Journal of Clinical Microbiology.

[21]  R. Betts,et al.  Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? , 2005, Transplantation proceedings.

[22]  L. R. Whybin,et al.  Diagnosis of and Screening for Cytomegalovirus Infection in Pregnant Women , 2005, Journal of Clinical Microbiology.

[23]  U. Neumann,et al.  Changing impact of cytomegalovirus in liver transplantation – a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[24]  B. Alexander,et al.  Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients , 2005, Transplantation.

[25]  D. Mutimer,et al.  Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus‐seropositive donors , 2005, Transplant infectious disease : an official journal of the Transplantation Society.

[26]  A. Limaye,et al.  Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis1 , 2004, Transplantation.

[27]  M. Isaacs,et al.  Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations , 2004, Journal of medical virology.

[28]  U. Settmacher,et al.  Prospective Evaluation of the Clinical Utility of Different Methods for the Detection of Human Cytomegalovirus Disease after Liver Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  A. Tenório,et al.  Different Cytomegalovirus Glycoprotein B Genotype Distribution in Serum and Cerebrospinal Fluid Specimens Determined by a Novel Multiplex Nested PCR , 2003, Journal of Clinical Microbiology.

[30]  L. Halme,et al.  Cytomegalovirus infection and development of biliary complications after liver transplantation1 , 2003, Transplantation.

[31]  N. Lurain,et al.  Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  Andrew K Burroughs,et al.  Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. , 2002, The Journal of infectious diseases.

[33]  G. Raghu,et al.  High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. , 2002, The Journal of infectious diseases.

[34]  C. Manichanh,et al.  Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. , 2001, The Journal of general virology.

[35]  M. Wilders-Truschnig,et al.  Cytomegalovirus diagnosis in renal and bone marrow transplant recipients: the impact of molecular assays. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[36]  C. Sabin,et al.  Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. , 2000, The Journal of infectious diseases.

[37]  A. Limaye,et al.  Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants , 2000, The Lancet.

[38]  C. Sabin,et al.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.

[39]  A. Burroughs,et al.  Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus , 1999, Journal of medical virology.

[40]  J. Rabkin,et al.  Association of cytomegalovirus genotype with graft rejection after liver transplantation. , 1998, Transplantation.

[41]  M. Jacobson.  Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.